Kenkare-Mitra Sara 4

What Happened
Sara Kenkare‑Mitra, a director of Unicycive Therapeutics, was granted two restricted stock unit (RSU) awards on May 14, 2026 (transaction code A). The grants total 126,300 RSUs: 84,200 RSUs and 42,100 RSUs. The awards were granted at $0.00 per share (awards/derivative securities payable in common stock); no cash changed hands at grant and no per‑share market value was reported on the Form 4.

Key Details

• Transaction date: 2026-05-14 (Form 4 filed 2026-05-21, a delayed filing).
• Grant details: 84,200 RSUs (Footnote F1) and 42,100 RSUs (Footnote F2), both recorded as awards (code A) with $0.00 acquisition price.
• Vesting: F1 — 84,200 RSUs vest 1/3 on each anniversary of the grant for three years, subject to continued service. F2 — 42,100 RSUs vest one year after the grant, subject to continued service.
• Shares owned after transaction: not disclosed in the provided filing.
• Filing timeliness: The Form 4 was filed seven days after the transaction date; this is a delayed filing and may be noted as late in SEC records.

Context
RSU grants are a common form of equity compensation and are different from open‑market purchases or sales — no immediate market trade occurred. These are derivative awards that convert into common shares only as they vest (subject to service conditions); tax withholding and share issuance typically occur at vesting. Because this is an award (not a purchase or sale), it should be viewed as compensation rather than a direct signal of buying or selling sentiment.